Sign in

    Mayank Mantani

    Research Analyst at B. Riley Securities

    Mayank Mantani is an Analyst at B. Riley Securities, specializing in healthcare and biotechnology sector research with a focus on companies such as Spectrum Pharmaceuticals and Novavax. He regularly contributes insights on earnings calls for these firms and others in the biotech sphere, demonstrating a detailed understanding of industry trends and company performance. Mantani has established his career as a healthcare equities analyst, joining B. Riley Securities to provide coverage of innovative biopharmaceutical companies, and has previously built experience through roles that developed his expertise in fundamental research and market analysis. He holds relevant securities licenses and maintains a reputation for thoughtful analysis in the biotechnology investment community.

    Mayank Mantani's questions to MiNK Therapeutics (INKT) leadership

    Mayank Mantani's questions to MiNK Therapeutics (INKT) leadership • Q2 2025

    Question

    Mayank Mantani of B. Riley Securities inquired about the trial design for the preventative Graft-versus-Host Disease (GVHD) study, including patient numbers and endpoints. He also asked for an update on the gastric cancer study and the company's plans for its targeted INKT program given its current cash position.

    Answer

    President and CEO Dr. Jennifer Buell explained that the Phase 1 GVHD trial will have a safety run-in followed by a 20-25 patient signal-seeking cohort at a target dose of one billion cells. For the gastric cancer program, she noted that mature follow-up data, including survival outcomes, is expected by year-end. Regarding the targeted INKT program, Dr. Buell stated that while the primary focus is on immune-mediated diseases, the engineered program has advanced significantly and can proceed to an IND with limited expense, potentially accelerated by a partnership.

    Ask Fintool Equity Research AI